Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pupil Dilation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Pupil Dilation. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-003252-37 Sponsor Protocol Number: OXYDILAT Start Date*: 2012-10-08
    Sponsor Name:Aarhus University Hospital, Department of Ophthalmology
    Full Title: The effect of topical anaesthesia on pharmacological mydriasis in patients screened for diabetic retinopathy
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10015919 - Eye disorders 10013007 Dilatation pupillary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-003279-28 Sponsor Protocol Number: LT2380-PII-11/07 Start Date*: 2008-07-24
    Sponsor Name:Laboratoires Théa
    Full Title: Efficacy and safety assessment of intracameral T2380 (Fixed combination of lidocaïne, phenylephrine and tropicamide) for anaesthesia and mydriasis in phacoemulsification cataract surgery
    Medical condition: The aim of the development was to develop a combination of active substances enabling to obtain at the same time a mydriasis and an anaesthesia during cataract surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002325 Anesthesia local LLT
    9.1 10011719 Cycloplegia PT
    9.1 10028521 Mydriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) BE (Ongoing) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002339-23 Sponsor Protocol Number: MydriasisbeiMydrane Start Date*: 2019-10-24
    Sponsor Name:Medical University Graz, Department of Ophtalmology
    Full Title: Prospective intraindividual comparison of the mydriasis of a standardized intracameral anaesthetics with the topical preoperative drop application in the uncomplicated cataract surgery
    Medical condition: patients who need a cataract surgery in both eyes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021188-34 Sponsor Protocol Number: LT2380-PIII-05/10 Start Date*: 2011-07-01
    Sponsor Name:Laboratoires Théa
    Full Title: Efficacy and safety assessment of intracameral T2380 (Fixed combination of lidocaine, phenylephrine and tropicamide) for mydriasis and anaesthesia in phacoemulsification cataract surgery
    Medical condition: The aim of this clinical study will be to develop a combination of active substances enabling to obtain at the same time a mydriasis and an anaesthesia during cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10011719 Cycloplegia PT
    14.1 10042613 - Surgical and medical procedures 10002325 Anesthesia local LLT
    14.1 10015919 - Eye disorders 10028521 Mydriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Ongoing) SE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003885-15 Sponsor Protocol Number: OMS302-ILR-006 Start Date*: 2014-01-06
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 3 Randomised, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter in Subjects at High Risk of Intraoperative Floppy Iris Syndrome Undergoing Int...
    Medical condition: Intraocular Lens Replacement (ILR) in subject at high risk for Intraoperative Floppy Iris Syndrome (IFIS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10054771 Intraocular lens replacement LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000867-25 Sponsor Protocol Number: OMS302-ILR-004 Start Date*: 2012-07-23
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 3 Randomised, Double-Masked, Placebo-Controlled Study of the Pharmacokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Un...
    Medical condition: Intraocular Lens Replacement with Pharmacoemulsification
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10054771 Intraocular lens replacement LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004686-18 Sponsor Protocol Number: 539 Start Date*: 2008-02-08
    Sponsor Name:Bausch&Lomb Dr Gerhard Mann chem.-Fabrik GmbH
    Full Title: A multicenter, Investigator-Masked, Parallel Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0.1% Eyedrops Compared with Ketorolac 0.5% Eyedrops in the Ocular Inflammation After...
    Medical condition: Prevention of ocular inflammation in adults patients undergoing cataract surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000581-23 Sponsor Protocol Number: CSPP100A2244 Start Date*: 2008-07-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-masked, placebo-controlled add on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema
    Medical condition: Diabetic Macular Edema (DME) in hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001149-15 Sponsor Protocol Number: LevoDesa_05-2017 Start Date*: 2018-07-31
    Sponsor Name:NTC SRL
    Full Title: Aqueous humour concentrations after topical apPlication of combinEd levofloxacin dexamethasone eye dRops and of its single components: a randoMized, assEssor-blinded, parallel-group study in patien...
    Medical condition: Patients for which cataract surgery has been planned.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007739 Cataract PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014983-20 Sponsor Protocol Number: DIA001 Start Date*: 2010-02-25
    Sponsor Name:Wockhardt UK Limited
    Full Title: An open label single dose pharmacokinetic study of Diamorphine Hydrochloride Nasal Spray (0.06mg/kg) in children
    Medical condition: The IMP is to be used as an analgesic for the relief of acute pain.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002182 Analgesia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014982-16 Sponsor Protocol Number: DIA002 Start Date*: 2010-02-25
    Sponsor Name:Wockhardt UK Limited
    Full Title: An open label, single dose safety study of Diamorphine Hydrochloride Nasal Spray (0.1mg/kg) in children
    Medical condition: The IMP is to be used as an analgesic for the relief of acute pain.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002182 Analgesia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004409-42 Sponsor Protocol Number: LRP/LUBT010/2016/008 Start Date*: 2020-11-23
    Sponsor Name:Lupin Limited (Biotechnology Division)
    Full Title: A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Neovascular Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005164-26 Sponsor Protocol Number: DS5565-A-E312 Start Date*: 2014-12-19
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia
    Medical condition: DS-5565 is being developed for the treatment of pain associated with fibromyalgia (FM).
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) AT (Completed) SK (Completed) EE (Completed) CZ (Completed) ES (Completed) LT (Completed) HU (Completed) LV (Completed) PT (Completed) SI (Completed) FI (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004579-22 Sponsor Protocol Number: 150998-005 Start Date*: 2015-08-24
    Sponsor Name:Allergan Ltd.
    Full Title: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration
    Medical condition: Neovascular age-related macular degeneration (AMD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) AT (Completed) LV (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004580-20 Sponsor Protocol Number: 150998-006 Start Date*: 2015-08-18
    Sponsor Name:Allergan Ltd.
    Full Title: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration
    Medical condition: Neovascular age-related macular degeneration (AMD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) IT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004157-66 Sponsor Protocol Number: QRK202 Start Date*: 2012-05-29
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003079-31 Sponsor Protocol Number: QRK207 Start Date*: 2016-10-20
    Sponsor Name:Quark Pharmaceuticals Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU...
    Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10068242 Nonarteritic anterior ischaemic optic neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000031-28 Sponsor Protocol Number: CLKA651X2202 Start Date*: 2019-04-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000946-24 Sponsor Protocol Number: 15-EI-0202 Start Date*: 2018-01-09
    Sponsor Name:National Eye Institute
    Full Title: Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration
    Medical condition: Geographic Atrophy Associated with Age-Related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-005601-22 Sponsor Protocol Number: poc1doxy Start Date*: 2008-03-27
    Sponsor Name:
    Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA